Stock BLTE BELITE BIO, INC
Add to a list
To use this feature you must be a member
Log inSign up

News Belite Bio, Inc

Equities

BLTE

US07782B1044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
45.03 USD -0.86% Intraday chart for Belite Bio, Inc +6.08% -1.57%
May. 14 Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024
May. 14 Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
GL
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
AQ
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Belite Bio's Q1 Loss Narrows
MT
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GL
Transcript : Belite Bio, Inc - Special Call
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GL
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
AQ
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GL
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
GL
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
GL
Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
CI
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
GL
Belite Bio Unveils Plan to Offer 651,380 American Depository Shares
MT
Belite Bio Announces $25 Million Registered Direct Offering
GL
Belite Bio : Initiates Stargardt Disease Clinical Trial in Japan
PU
Belite Bio : Announces MHRA Submission of Tinlarebant for Stargardt Disease Clinical Trial in the United Kingdom
PU
Belite Bio : Submits US IND Amendment to Initiate a Phase 2/3 Clinical Trial of Tinlarebant in Stargardt Disease
PU
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BLTE Stock
  4. News Belite Bio, Inc